Metabolic Abnormalities Associated with the Use of Protease Inhibitors and Non-Nucleoside Reverse Transcriptase Inhibitors‪.‬

Abstract: The use of protease inhibitors and non-nucleoside reverse transcriptase inhibitors for the treatment of HIV infection and AIDS has been associated with multiple abnormalities in glucose and lipid metabolism. Specifically, these abnormalities include insulin resistance, increased triglycerides and increased LDL cholesterol levels. The metabolic disturbances are due to a combination of factors, including the direct effect of medications, restoration to health and HIV disease, as well as individual genetic predisposition. Of the available anti-retroviral medications, indinavir has been associated with causing the most insulin resistance and ritonavir with causing the most hypertriglyceridemia. Key words: HIV, glucose, lipids, protease inhibitor, antiretroviral